Skip to main content
. Author manuscript; available in PMC: 2023 Sep 7.
Published in final edited form as: Clin Pediatr (Phila). 2016 Oct 13;56(8):729–736. doi: 10.1177/0009922816673401

Table 2.

EBD Medication Use Among All Children Aged 4 to 17 With Diagnosed ADHD (n = 3504) and First Prescriber of EBD Medication Among Children With Diagnosed ADHD Using EBD Medication (n = 1898) by Health Insurance: United States, 2010 to 2013.

Percent Who Used Medication for EBD During Past 6 Months (n = 1898) SE P a Percent With Medication First Prescribed by a Pediatrician or Other Family Doctor (n = 1373) SE Percent With Medication First Prescribed by a Psychiatrist, Psychologist, or Other Mental Health Professional (n = 453) SE Percent With Medication First Prescribed by Another Type of Physician (n = 49) SE P a
Total 56.0 1.0 72.9 1.3 24.5 1.2 2.6 0.5
Unadjusted results
Health insurance <.001 <.01
 Private 57.3 1.5 75.2 1.8 22.0 1.8 2.8 0.6
 Public 57.0 1.5 69.5 2.0 28.1 1.9 2.4 0.6
 Uninsured 33.1 4.5 85.0 5.7 14.8 5.7 c
Adjusted results b
Health insurance <.001 <.01
 Private 56.4 1.5 75.5 1.8 21.4 1.8 3.1 0.7
 Public 57.9 1.6 69.0 2.1 28.8 2.0 2.1 0.5
 Uninsured 33.5 4.5 84.7 5.7 15.1 5.7 c

Abbreviations: EBD, emotional and behavioral difficulties; ADHD, attention-deficit/hyperactivity disorder; SE, standard error.

a

P values are from χ2 tests for unadjusted values and F tests for adjusted values.

b

Adjusted results are adjusted for age, sex, race/ethnicity, and comorbidities. Comorbidities include a parent-reported diagnosed condition of Down syndrome, intellectual disability, developmental delay, autism, or learning disability, or current symptoms of seizures, frequent headaches, or stuttering.

c

Unreliable estimate.